Albany molecular research, INC(amri)[19-002417]mcsp task order XU project - exploratory chemistry POP: TBD
Ended Awarded Last action
- Contract number
- 75N95019F00064
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $555,782
Award facts
- Opportunity
-
- NIHNINDS1701 Solicitation number
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Mar 19, 2018
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Jun 30, 2017
- Contract value 17% obligated
-
- $555,782.32 Current, with exercised options
- $3,349,436.46 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Funding Only Action | -$19,560 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Original award | $575,342 |
About this award
This is a $3,349,436.46 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as AMRI. The contract is part of NINDS's Medicinal Chemistry Support Program for Therapeutic Development, which focuses on early-stage drug discovery research.
The contract provides for exploratory chemistry and other pharmaceutical research and development services to support NINDS's scientific initiatives, which may span therapeutic areas like neurology, infectious diseases, substance abuse, and translational sciences. As a large business contractor, Curia Global Inc. has demonstrated extensive expertise in highly specialized pharmaceutical R&D through numerous prior awards from NINDS and other NIH institutes. The contract does not have a small business set-aside designation.
Quick answers
Who was awarded contract 75N95019F00064?
75N95019F00064 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on November 30, 2018.
How much is contract 75N95019F00064 worth?
The government has obligated $555,782 on 75N95019F00064. Its potential value, with all options, is $3,349,436.
Which agency awarded contract 75N95019F00064?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00064, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95019F00064 an order under another contract?
Yes. 75N95019F00064 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95019F00064 competed?
The extent of competition for 75N95019F00064 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award